These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 29151522)

  • 1. Large Cell Neuroendocrine Carcinoma Harboring an Anaplastic Lymphoma Kinase (ALK) Rearrangement with Response to Alectinib.
    Hayashi N; Fujita A; Saikai T; Takabatake H; Sotoshiro M; Sekine K; Kawana A
    Intern Med; 2018 Mar; 57(5):713-716. PubMed ID: 29151522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Case of ALK-Rearranged Combined Lung Adenocarcinoma and Neuroendocrine Carcinoma with Diffuse Bone Metastasis and Partial Response to Alectinib.
    Lim CA; Banyi N; Tucker T; Ionescu DN; Melosky B
    Curr Oncol; 2022 Feb; 29(2):848-852. PubMed ID: 35200571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of ALK Immunohistochemistry for Optimal Therapeutic Strategy of Pulmonary Large-cell Neuroendocrine Carcinoma and Identification of a Novel
    Shimizu N; Akashi Y; Fujii T; Shiono H; Yane K; Kitahara T; Ohta Y; Kakudo K; Wakasa T
    Anticancer Res; 2019 Jan; 39(1):413-420. PubMed ID: 30591488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ALK-rearranged lung squamous cell carcinoma responding to alectinib: a case report and review of the literature.
    Mamesaya N; Nakashima K; Naito T; Nakajima T; Endo M; Takahashi T
    BMC Cancer; 2017 Jul; 17(1):471. PubMed ID: 28683775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequential Therapy with Crizotinib and Alectinib in ALK-Rearranged Non-Small Cell Lung Cancer-A Multicenter Retrospective Study.
    Ito K; Hataji O; Kobayashi H; Fujiwara A; Yoshida M; D'Alessandro-Gabazza CN; Itani H; Tanigawa M; Ikeda T; Fujiwara K; Fujimoto H; Kobayashi T; Gabazza EC; Taguchi O; Yamamoto N
    J Thorac Oncol; 2017 Feb; 12(2):390-396. PubMed ID: 27498387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Alectinib and mixed large cell neuroendocrine carcinoma of the lung.].
    Hegedűs F; Sükösd F; Tiszlavicz L; Furák J; Pálföldi R; Fejes Z; Zombori T
    Orv Hetil; 2023 Apr; 164(14):548-554. PubMed ID: 37031440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Next-Generation Sequencing Identified a Novel Crizotinib-Sensitive PLB1-ALK Rearrangement in Lung Large-Cell Neuroendocrine Carcinoma.
    Wang S; Wu X; Zhao J; Chen H; Zhang Z; Wang M; Xu C; Wang Y; Wang L; He Z; Wang Q
    Clin Lung Cancer; 2021 May; 22(3):e366-e370. PubMed ID: 32651063
    [No Abstract]   [Full Text] [Related]  

  • 8. Successful oral desensitization against skin rash induced by alectinib in a patient with anaplastic lymphoma kinase-positive lung adenocarcinoma: A case report.
    Shirasawa M; Kubotaa M; Harada S; Niwa H; Kusuhara S; Kasajima M; Hiyoshi Y; Ishihara M; Igawa S; Masuda N
    Lung Cancer; 2016 Sep; 99():66-8. PubMed ID: 27565916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progression-Free and Overall Survival of Patients With ALK Rearrangement-Positive Non-Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib.
    Watanabe S; Hayashi H; Okamoto K; Fujiwara K; Hasegawa Y; Kaneda H; Tanaka K; Takeda M; Nakagawa K
    Clin Lung Cancer; 2016 Nov; 17(6):528-534. PubMed ID: 27318655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metastatic Large-Cell Neuroendocrine Lung Carcinoma With ALK Fusion Oncogene With Partial Response to Alectinib.
    Leblanc A; Owen S; Fiset PO; Gomez Corrador AL; Isenberg J; Bouganim N
    JCO Precis Oncol; 2021 Nov; 5():802-807. PubMed ID: 34994612
    [No Abstract]   [Full Text] [Related]  

  • 11. Heterogeneous Tumor-Immune Microenvironments between Primary and Metastatic Tumors in a Patient with
    Tashiro T; Imamura K; Tomita Y; Tamanoi D; Takaki A; Sugahara K; Sato R; Saruwatari K; Sakata S; Inaba M; Ushijima S; Hirata N; Sakagami T
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pulmonary Adenocarcinoma, Harboring Both an EGFR Mutation and ALK Rearrangement, Presenting a Stable Disease to Erlotinib and a Partial Response to Alectinib.
    Yokoyama A; Tamura A; Miyakawa K; Kusaka K; Shimada M; Hirose T; Matsui H; Kitani M; Hebisawa A; Ohta K
    Intern Med; 2018 Aug; 57(16):2377-2382. PubMed ID: 29526950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dramatic response to alectinib in a patient of ALK-rearranged lung cancer with poor performance status.
    Tanaka H; Taima K; Morimoto T; Nakamura K; Tanaka Y; Itoga M; Takanashi S; Okumura K
    BMC Res Notes; 2016 Mar; 9():173. PubMed ID: 26987388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of CD 133 and BCL-2 in non-small cell lung cancer with neuroendocrine differentiation after transformation in ALK rearrangement-positive adenocarcinoma.
    Koyama K; Katsurada N; Jimbo N; Tachihara M; Tamura D; Nakata K; Nagano T; Yamamoto M; Kamiryo H; Kobayashi K; Itoh T; Nishimura Y
    Pathol Int; 2019 May; 69(5):294-299. PubMed ID: 30900377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dramatic response to alectinib in a patient with ALK-rearranged squamous cell lung cancer.
    Shiihara J; Ohyanagi F; Amari H; Toda M; Tahara H; Yuzawa M; Maeda Y; Nomura M; Mizushina Y; Nagai Y; Ohta H; Yamaguchi Y
    Thorac Cancer; 2021 Sep; 12(17):2420-2423. PubMed ID: 34324792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severe acute interstitial lung disease in a patient with anaplastic lymphoma kinase rearrangement-positive non-small cell lung cancer treated with alectinib.
    Yamamoto Y; Okamoto I; Otsubo K; Iwama E; Hamada N; Harada T; Takayama K; Nakanishi Y
    Invest New Drugs; 2015 Oct; 33(5):1148-50. PubMed ID: 26334220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosis and Treatment of Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer.
    Arbour KC; Riely GJ
    Hematol Oncol Clin North Am; 2017 Feb; 31(1):101-111. PubMed ID: 27912826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transformation of ALK rearrangement-positive adenocarcinoma to small-cell lung cancer in association with acquired resistance to alectinib.
    Takegawa N; Hayashi H; Iizuka N; Takahama T; Ueda H; Tanaka K; Takeda M; Nakagawa K
    Ann Oncol; 2016 May; 27(5):953-5. PubMed ID: 26811347
    [No Abstract]   [Full Text] [Related]  

  • 19. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
    Gadgeel SM; Gandhi L; Riely GJ; Chiappori AA; West HL; Azada MC; Morcos PN; Lee RM; Garcia L; Yu L; Boisserie F; Di Laurenzio L; Golding S; Sato J; Yokoyama S; Tanaka T; Ou SH
    Lancet Oncol; 2014 Sep; 15(10):1119-28. PubMed ID: 25153538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid and dramatic response to alectinib in an anaplastic lymphoma kinase rearranged non-small-cell lung cancer patient who is critically ill.
    Yoshida T; Hida T; Yatabe Y
    Anticancer Drugs; 2016 Jul; 27(6):573-5. PubMed ID: 26938871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.